These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 10612226)
1. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism]. Schwenk A Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226 [No Abstract] [Full Text] [Related]
2. Adverse drug reactions to protease inhibitors. Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251 [TBL] [Abstract][Full Text] [Related]
3. Effects of sex and race on lipodystrophy pathogenesis. Nolan D; Mallal S J HIV Ther; 2001 May; 6(2):32-6. PubMed ID: 11501201 [No Abstract] [Full Text] [Related]
4. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy. Smith D J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199 [No Abstract] [Full Text] [Related]
5. Changes in body shape and metabolic abnormalities. Res Initiat Treat Action; 1999 Jan; 5(1):18. PubMed ID: 11366225 [TBL] [Abstract][Full Text] [Related]
6. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir. Moyle GJ AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769 [No Abstract] [Full Text] [Related]
7. Fat, sugar and drugs on the French Riviera. Lands L GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205 [TBL] [Abstract][Full Text] [Related]
8. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]. Dieleman JP; Hillebrand-Haverkort ME; van der Ende ME; Sturkenboom MC; Lange JM; Stricker BH Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2856-60. PubMed ID: 10065260 [TBL] [Abstract][Full Text] [Related]
11. Are changes in body shape due to drug side effects? TreatmentUpdate; 1999 Jun; 11(4):3-4. PubMed ID: 11366790 [TBL] [Abstract][Full Text] [Related]
12. On the trail of fugitive fat: the chase turns to NRTIs. Mascolini M J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871 [TBL] [Abstract][Full Text] [Related]
13. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk? Gilleece Y; Nelson M J HIV Ther; 2001 May; 6(2):37-9. PubMed ID: 11501202 [No Abstract] [Full Text] [Related]
14. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. Fantoni M; Del Borgo C; Autore C; Barbaro G Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561 [TBL] [Abstract][Full Text] [Related]
16. Hyperlipidemia and inhibitors of HIV protease. Distler O; Cooper DA; Deckelbaum RJ; Sturley SL Curr Opin Clin Nutr Metab Care; 2001 Mar; 4(2):99-103. PubMed ID: 11224652 [TBL] [Abstract][Full Text] [Related]
17. [Lipodystrophy and metabolic disorders in anti-HIV therapy]. Behrens GM; Stoll M; Schmidt RE MMW Fortschr Med; 2000 Mar; 142 Suppl 1():68-71. PubMed ID: 10863318 [TBL] [Abstract][Full Text] [Related]
18. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Calza L; Manfredi R; Chiodo F J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323 [TBL] [Abstract][Full Text] [Related]
19. [Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data]. Urso R; Croce GF; Tubili C; De Marco M; La Scala P; Luglio D; Narciso P Recenti Prog Med; 2000 Feb; 91(2):78-85. PubMed ID: 10748653 [TBL] [Abstract][Full Text] [Related]